Format

Send to

Choose Destination
Trends Pharmacol Sci. 2006 Dec;27(12):626-30. Epub 2006 Oct 19.

Novel modulators of poly(ADP-ribose) polymerase.

Author information

1
Department of Surgery, University of Medicine and Dentistry, New Jersey Medical School, 185 South Orange Avenue, University Heights Newark, NJ 07103, USA. szabocsaba@aol.com

Abstract

The nuclear enzyme poly(ADP-ribose) polymerase (PARP)-1 has an important role in regulating cell death and cellular responses to DNA repair. Pharmacological inhibitors of PARP have entered clinical testing as cytoprotective agents in cardiovascular diseases and as adjunct antitumor therapeutics. Initially, it was assumed that the regulation of PARP occurs primarily at the level of DNA breakage: recognition of DNA breaks was considered to be the primary regulator (activator) or the catalytic activity of PARP. Recent studies have provided evidence that PARP-1 activity can also be modulated by several endogenous factors, including various kinases, purines and caffeine metabolites. There is a gender difference in the contribution of PARP-1 to stroke and inflammatory responses, which is due, at least in part, to endogenous estrogen levels. Several tetracycline antibiotics are also potent PARP-1 inhibitors. In this article, we present an overview of novel PARP-1 modulators.

PMID:
17055069
PMCID:
PMC2228253
DOI:
10.1016/j.tips.2006.10.003
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center